Tiopronin is a thiol agent indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria.

Brand Names
Generic Name
DrugBank Accession Number

Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output.

Tiopronin may also be used to bind metal nanoparticles in Wilson's disease, which is an overload of copper in the body. It has been investigated for use in the treatment of arthritis and as a neuroprotective agent in aneurysmal subarachnoid hemorrhage.

Small Molecule
Approved, Investigational
Average: 163.19
Monoisotopic: 163.030314328
Chemical Formula
  • Tiopronin
  • Tiopronine
  • Tiopronino
  • Tioproninum



Tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mg/day, and who have failed treatment with non-pharmacological measures of increased fluid intake, decreased sodium and protein intake, and urine alkalinization.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofKidney stone formation••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Not Available

Mechanism of action

Kidney stones form when the solubility limit is exceeded and urine becomes supersaturated with endogenous cystine. Tiopronin is an active reducing agent which undergoes a thiol-disulfide exchange with cystine to form a water-soluble mixed disulfide complex. Thus, the amount of sparingly soluble cystine is reduced. By reducing urinary cystine concentrations below the solubility limit, tiopronin helps reduce cystine stone formation.


Tiopronin undergoes slow absorption, reaching peak plasma concentration 3-6 hours after ingestion. In a study of healthy subjects, the bioavailability of total and unbound tiopronin was found to be 63% and 40%, respectively.

Volume of distribution

The volume of distribution of tiopronin is high at 455 L, indicating that a large portion of the drug is bound to tissues outside plasma.

Protein binding

Tiopronin undergoes extensive protein binding in plasma. It is thought that this occurs through the formation of a disulphide bridge to the free thiol group of albumin.


The principle metabolite of tiopronin is 2-mercaptopropionic acid (2-MPA). Between 10-15% of the drug is metabolized to 2-MPA via hydrolysis.

Hover over products below to view reaction partners

Route of elimination

Tiopronin is 100% excreted in urine.


Tiopronin has a long terminal half life of 53 hours in healthy subjects. However, the unbound drug fraction of tiopronin is eliminated much more rapidly from plasma with a calculated half life of 1.8 hours.


Total renal clearance for the total and unbound fractions of tiopronin were found to be 3.3 and 13.3 L/h respectively.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

Long-term carcinogenicity and mutagenicity studies have not been performed with tiopronin. In experimental animal studies, high doses of tiopronin were shown to interfere with the maintenance of pregnancy and viability of a fetus. No neural tube defects were detected when tiopronin was given to mice and rats in doses up to 10 times the highest recommended human dose. However, the manufacturer does not rule out the possibility of teratogenicity, as it has been seen with the drug d-penicillamine, which acts with a similar mechanism to tiopronin. Tiopronin is not recommended for use in breastfeeding mothers and has no established safety in children 9 years old or younger. There have been case reports of tiopronin-related nephropathy.

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbacavirAbacavir may decrease the excretion rate of Tiopronin which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Tiopronin which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Tiopronin which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.
Food Interactions
  • Take at the same time every day. Take each dose at the same time every day.
  • Take on an empty stomach. Take tiopronin at least 1 hour before or 2 hours after eating food.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Acadione (Sanofi-Aventis France) / Capen / Captimer (MIT Gesundheit) / Epatiol (Medici Italy) / Kai Na / Mucosyt (Bioprogress) / Sutilan / Thiola / Vincol
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ThiolaTablet, sugar coated100 mg/1OralMission Pharmacal Company1988-08-11Not applicableUS flag
Thiola ECTablet, delayed release300 mg/1OralMission Pharmacal Company2019-06-28Not applicableUS flag
Thiola ECTablet, delayed release100 mg/1OralMission Pharmacal Company2019-06-28Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
TioproninTablet, delayed release300 mg/1OralTorrent Pharmaceuticals Limited2024-01-30Not applicableUS flag
TioproninTablet, delayed release300 mg/1OralAmneal Pharmaceuticals NY LLC2023-08-16Not applicableUS flag
TioproninTablet, delayed release300 mg/ 11OralENDO USA, Inc.2024-06-26Not applicableUS flag
TioproninTablet, sugar coated100 mg/1OralTeva Pharmaceuticals USA, Inc.2021-05-17Not applicableUS flag
TioproninTablet, delayed release100 mg/1OralENDO USA, Inc.2024-06-26Not applicableUS flag


ATC Codes
G04BX16 — Tiopronin
Drug Categories
Chemical TaxonomyProvided by Classyfire
This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
Organic compounds
Super Class
Organic acids and derivatives
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-alpha amino acids
Alternative Parents
Secondary carboxylic acid amides / Monocarboxylic acids and derivatives / Carboxylic acids / Alkylthiols / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Aliphatic acyclic compound / Alkylthiol / Carbonyl group / Carboxamide group / Carboxylic acid / Hydrocarbon derivative / Monocarboxylic acid or derivatives / N-acyl-alpha-amino acid / Organic nitrogen compound / Organic oxide
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
N-acyl-amino acid (CHEBI:32229)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
InChI Key
2-(2-sulfanylpropanamido)acetic acid


General References
  1. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR: Medical management of kidney stones: AUA guideline. J Urol. 2014 Aug;192(2):316-24. doi: 10.1016/j.juro.2014.05.006. Epub 2014 May 20. [Article]
  2. Lindell A, Denneberg T, Jeppsson JO: Urinary excretion of free cystine and the tiopronin-cysteine-mixed disulfide during long term tiopronin treatment of cystinuria. Nephron. 1995;71(3):328-42. [Article]
  3. Giannakopoulos X, Kalfakakou V, Tsoumanis P, Karkabounas S, Giannakis D, Chambilomatis P, Evangelou A, Kallistratos G: [Results of treatment of cystinuria and cystine lithiasis with alpha-mercaptopropionylglycine. Apropos of 40 patients]. J Urol (Paris). 1994;100(3):129-34. [Article]
  4. Carlsson MS, Denneberg T, Emanuelsson BM, Kagedal B, Lindgren S: Pharmacokinetics of oral tiopronin. Eur J Clin Pharmacol. 1993;45(1):79-84. [Article]
  5. Hercelin B, Leroy P, Nicolas A, Gavriloff C, Chassard D, Thebault JJ, Reveillaud MT, Salles MF, Netter P: The pharmacokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers. Eur J Clin Pharmacol. 1992;43(1):93-5. [Article]
  6. Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV: Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol. 1986 Nov;136(5):1003-8. [Article]
  7. Kim GH, Kellner CP, Hickman ZL, Zacharia BE, Starke RM, Hwang BY, Ducruet AF, Fernandez L, Mayer SA, Tracey KJ, Connolly ES Jr: A phase I clinical trial of tiopronin, a putative neuroprotective agent, in aneurysmal subarachnoid hemorrhage. Neurosurgery. 2010 Jul;67(1):182-5; discussion 186. doi: 10.1227/01.NEU.0000370919.93259.3C. [Article]
  8. Dolin DJ, Asplin JR, Flagel L, Grasso M, Goldfarb DS: Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol. 2005 Apr;19(3):429-32. [Article]
  9. Remien A, Kallistratos G, Burchardt P: Treatment of cystinuria with Thiola (alpha-mercaptopropionyl glycine). Eur Urol. 1975;1(5):227-8. [Article]
  10. Zheng Z, Xue Y, Jia J, Wei L, Shang W, Lin S: Tiopronin-induced membranous nephropathy: a case report. Ren Fail. 2014 Oct;36(9):1455-60. doi: 10.3109/0886022X.2014.926754. Epub 2014 Jul 16. [Article]
  11. Alvarez Navascues R, Vidau Arguelles P, Rodriguez Suarez C, Herrera Perez de Villar J, Suarez Heiva M: [Nephrotic syndrome and anasarca status, secondary to treatment with tiopronin in a case of cystinuria]. Arch Esp Urol. 2001 Jun;54(5):438-40. [Article]
KEGG Compound
PubChem Compound
PubChem Substance
Drugs.com Drug Page
Download (27.4 KB)

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedTreatmentCystinuria1somestatusstop reasonjust information to hide
2CompletedTreatmentAneurysmal Subarachnoid Hemorrhage (A-sah)1somestatusstop reasonjust information to hide
2CompletedTreatmentCystinuria1somestatusstop reasonjust information to hide
2CompletedTreatmentDrug Induced Liver Injury1somestatusstop reasonjust information to hide


Not Available
Not Available
Dosage Forms
Granule600 MG
Suppository100 MG
Suppository200 MG
Suppository50 MG
Suppository600 MG
Tablet600 MG
Tablet, sugar coatedOral100 mg/1
Tablet, delayed releaseOral100 mg/1
Tablet, delayed releaseOral300 mg/1
Tablet, delayed releaseOral300 mg/ 11
Not Available
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US11458104No2018-11-142038-11-14US flag


Experimental Properties
Not Available
Predicted Properties
pKa (Strongest Acidic)3.86Chemaxon
pKa (Strongest Basic)-4.2Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area66.4 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity37.77 m3·mol-1Chemaxon
Polarizability15.31 Å3Chemaxon
Number of Rings0Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03xr-9600000000-336996d138a3518dea07
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-9000000000-9032ff406775eec3b316
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-6c478ab00cdab89e428d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-9100000000-0f4384e80e6e5a68ac7f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0bu0-9000000000-b56441bbb4dbdbda5855
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01q9-9000000000-411844bc2fc275b9ba30
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
DeepCCS 1.0 (2019)
DeepCCS 1.0 (2019)
DeepCCS 1.0 (2019)


Pharmacological action
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
Uniprot ID
Uniprot Name
Molecular Weight
83867.71 Da
  1. Cuperus RA, Muijsers AO, Wever R: Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes. A therapeutic mechanism of these drugs in rheumatoid arthritis? Arthritis Rheum. 1985 Nov;28(11):1228-33. [Article]

Drug created at September 14, 2010 16:21 / Updated at February 21, 2021 18:52